NCT07006012View on ClinicalTrials.gov

RGL-305+ Lymphoma + Exploratory Clinical Study

NARecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

December 31, 2031

Conditions
Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
Interventions
DRUG

RGL-305

RGL-305 is administered intravenously with a recommended rate of 3-5 mL /min. The interval after the first administration was 3 weeks, and then every 2 weeks was a cycle, each cycle was given d1, and up to 5 cycles of cell transfusion were received.

Trial Locations (1)

201200

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER